[¹⁸F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma following BRAF-Targeted Therapy

References

1. 1.↵
   1. Hundahl SA,
   2. Fleming ID,
   3. Fremgen AM, et al

   . A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 1998;83:2638–48 doi:10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Xu B,
   2. Fuchs T,
   3. Dogan S, et al

   . Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 2020;30:1505–17 doi:10.1089/thy.2020.0086 pmid:32284020

   CrossRefPubMed
3. 3.↵
   1. Zhang K,
   2. Wang X,
   3. Wei T, et al

   . Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation. Front Endocrinol (Lausanne) 2024;15:1347362 doi:10.3389/fendo.2024.1347362 pmid:38544687

   CrossRefPubMed
4. 4.↵
   1. Wang JR,
   2. Montierth M,
   3. Xu L, et al

   . Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma. JCO Precis Oncol 2022;6:e2100504 doi:10.1200/PO.21.00504 pmid:35977347

   CrossRefPubMed
5. 5.↵
   DailyMed. TAFINLAR-dabrafenib capsule TAFINLAR-dabrafenib tablet, for suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea
6. 6.↵
   1. Hamidi S,
   2. Dadu R,
   3. Zafereo ME, et al

   . Initial management of BRAF V600E-variant anaplastic thyroid cancer: the FAST Multidisciplinary Group Consensus Statement. JAMA Oncol 2024;10:1264–71 doi:10.1001/jamaoncol.2024.2133 pmid:38990526

   CrossRefPubMed
7. 7.↵
   1. Maniakas A,
   2. Dadu R,
   3. Busaidy NL, et al

   . Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol 2020;6:1397–404 doi:10.1001/jamaoncol.2020.3362

   CrossRefPubMed
8. 8.↵
   1. Zhao X,
   2. Wang JR,
   3. Dadu R, et al

   . Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid 2023;33:484–91 doi:10.1089/thy.2022.0504

   CrossRefPubMed
9. 9.↵
   1. Hamidi S,
   2. Iyer PC,
   3. Dadu R, et al

   . Checkpoint inhibition in addition to dabrafenib/trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 2024;34:336–46 doi:10.1089/thy.2023.0573 pmid:38226606

   CrossRefPubMed
10. 10.↵
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Thryoid Carcinoma 2024:54–59. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470
11. 11.↵
    1. Bible KC,
    2. Kebebew E,
    3. Brierley J, et al

    . 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 2021;31:337–86 doi:10.1089/thy.2020.0944

    CrossRefPubMed
12. 12.↵
    1. Grabellus F,
    2. Nagarajah J,
    3. Bockisch A, et al

    . Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37:121–27 doi:10.1097/RLU.0b013e3182393599

    CrossRefPubMed
13. 13.↵
    1. Bossuyt PM,
    2. Reitsma JB,
    3. Bruns DE, et al

    ; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 2015;277:826–32 doi:10.1148/radiol.2015151516

    CrossRefPubMed
14. 14.↵
    1. Robbins KT,
    2. Shaha AR,
    3. Medina JE, et al

    ; Committee for Neck Dissection Classification, American Head and Neck Society. Consensus Statement on the Classification and Terminology of Neck Dissection. Arch Otolaryngol Head Neck Surg 2008;134:536–38 doi:10.1001/archotol.134.5.536 pmid:18490577

    CrossRefPubMed
15. 15.↵
    1. Sugawara Y,
    2. Zasadny KR,
    3. Neuhoff AW, et al

    . Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213:521–25 doi:10.1148/radiology.213.2.r99nv37521 pmid:10551235

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Zasadny KR,
    2. Wahl RL

    . Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–50 doi:10.1148/radiology.189.3.8234714

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Wahl RL,
    2. Jacene H,
    3. Kasamon Y, et al

    . From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S–50S doi:10.2967/jnumed.108.057307

    Abstract/FREE Full Text
18. 18.↵
    1. Ibrahimpasic T,
    2. Ghossein R,
    3. Shah JP, et al

    . Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 2019;29:311–21 doi:10.1089/thy.2018.0509

    CrossRefPubMed
19. 19.↵
    1. Nagarajah J,
    2. Ho AL,
    3. Tuttle RM, et al

    . Correlation of BRAFv600e mutation and glucose metabolism in thyroid cancer patients: an 18F-FDG PET study. J Nucl Med 2015;56:662–67 doi:10.2967/jnumed.114.150607

    Abstract/FREE Full Text
20. 20.↵
    1. Youden WJ

    . Index for rating diagnostic tests. Cancer 1950;3:32–35 doi:10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Ruopp MD,
    2. Perkins NJ,
    3. Whitcomb BW, et al

    . Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biometrical J 2008;50:419–30 doi:10.1002/bimj.200710415

    CrossRef
22. 22.↵
    1. Grünwald F,
    2. Kälicke T,
    3. Feine U, et al

    . Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547–52 doi:10.1007/s002590050493 pmid:10638405

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Kim H,
    2. Na KJ,
    3. Choi JH, et al

    . Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer. Eur Arch Otorhinolaryngol 2016;273:1569–76 doi:10.1007/s00405-015-3640-7 pmid:25971994

    CrossRefPubMed
24. 24.↵
    1. Kim HJ,
    2. Chang H-S,
    3. Ryu YH

    . Prognostic role of pre-treatment [18F]FDG PET/CT in patients with anaplastic thyroid cancer. Cancers (Basel) 2021;13:4228 doi:10.3390/cancers13164228

    CrossRefPubMed
25. 25.↵
    1. Pryma DA,
    2. Schöder H,
    3. Gönen M, et al

    . Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med 2006;47:1260–66 pmid:16883003

    Abstract/FREE Full Text
26. 26.↵
    1. Schreinemakers JM,
    2. Vriens MR,
    3. Munoz-Perez N, et al

    . Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management. World J Surg Oncol 2012;10:192 doi:10.1186/1477-7819-10-192 pmid:22985118

    CrossRefPubMed
27. 27.↵
    1. Manohar P,
    2. Beesley LJ,
    3. Bellile E, et al

    . Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine refractory differentiated thyroid cancer. Clin Nucl Med 2018;43:641–47 doi:10.1097/RLU.0000000000002193 pmid:30015659

    CrossRefPubMed
28. 28.↵
    1. Mansfield AS,
    2. Murphy SJ,
    3. Harris FR, et al

    . Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann Oncol 2016;27:2111–17 doi:10.1093/annonc/mdw405 pmid:27742657

    CrossRefPubMed
29. 29.↵
    1. Schrenk KG,
    2. Weschenfelder W,
    3. Spiegel C, et al

    . Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. J Cancer Res Clin Oncol 2023;149:5493–96 doi:10.1007/s00432-022-04496-y pmid:36469155

    CrossRefPubMed
30. 30.
    1. Tuttle RM,
    2. Haugen B,
    3. Perrier ND

    . Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid 2017;27:751–56 doi:10.1089/thy.2017.0102 pmid:28463585

    CrossRefPubMed